tetano
Editor, Senior Moderator
Oxf Open Immunol
. 2023 Jan 6;4(1):iqac012.
doi: 10.1093/oxfimm/iqac012. eCollection 2023.
Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals
Ashwini Kurshan[SUP] 1 [/SUP], Luke B Snell[SUP] 1 2 [/SUP], Lucie Prior[SUP] 1 [/SUP], Jerry C H Tam[SUP] 1 [/SUP], Carl Graham[SUP] 1 [/SUP], Rajeni Thangarajah[SUP] 3 4 [/SUP], Jonathan D Edgeworth[SUP] 2 [/SUP], Gaia Nebbia[SUP] 2 [/SUP], Katie J Doores[SUP] 1 [/SUP]
Affiliations
Abstract
Neutralizing monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein have been developed for the treatment of COVID-19. Whilst antibody therapy has been shown to reduce the risk of COVID-19-associated hospitalization and death, there is limited understanding of the endogenous immunity to SARS-CoV-2 generated in mAb-treated patients and therefore ongoing susceptibility to future infections. Here we measure the endogenous antibody response in SARS-CoV-2-infected individuals treated with REGN-COV2 (Ronapreve). We show that in the majority of unvaccinated, delta-infected REGN-COV2-treated individuals, an endogenous antibody response is generated, but, like untreated, delta-infected individuals, there was a limited neutralization breadth. However, some vaccinated individuals who were seronegative at SARS-CoV-2 infection baseline and some unvaccinated individuals failed to produce an endogenous immune response following infection and REGN-COV2 treatment demonstrating the importance of mAb therapy in some patient populations.
. 2023 Jan 6;4(1):iqac012.
doi: 10.1093/oxfimm/iqac012. eCollection 2023.
Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals
Ashwini Kurshan[SUP] 1 [/SUP], Luke B Snell[SUP] 1 2 [/SUP], Lucie Prior[SUP] 1 [/SUP], Jerry C H Tam[SUP] 1 [/SUP], Carl Graham[SUP] 1 [/SUP], Rajeni Thangarajah[SUP] 3 4 [/SUP], Jonathan D Edgeworth[SUP] 2 [/SUP], Gaia Nebbia[SUP] 2 [/SUP], Katie J Doores[SUP] 1 [/SUP]
Affiliations
- PMID: 36844257
- PMCID: PMC9914479
- DOI: 10.1093/oxfimm/iqac012
Abstract
Neutralizing monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein have been developed for the treatment of COVID-19. Whilst antibody therapy has been shown to reduce the risk of COVID-19-associated hospitalization and death, there is limited understanding of the endogenous immunity to SARS-CoV-2 generated in mAb-treated patients and therefore ongoing susceptibility to future infections. Here we measure the endogenous antibody response in SARS-CoV-2-infected individuals treated with REGN-COV2 (Ronapreve). We show that in the majority of unvaccinated, delta-infected REGN-COV2-treated individuals, an endogenous antibody response is generated, but, like untreated, delta-infected individuals, there was a limited neutralization breadth. However, some vaccinated individuals who were seronegative at SARS-CoV-2 infection baseline and some unvaccinated individuals failed to produce an endogenous immune response following infection and REGN-COV2 treatment demonstrating the importance of mAb therapy in some patient populations.